SAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) has revealed that its Board of Directors has approved a new program to buy back shares, allowing the company to repurchase up to $500 million worth of its shares, depending on market conditions. This new authorization comes on top of the $300 million accelerated repurchase program that was announced in October 2024 and finished in early February 2025.
We have put together a list of 10 companies that reflect the market's negative sentiment from Friday. In this article, we will examine how Neurocrine Biosciences Inc. (NASDAQ:NBIX) compares to the other stocks. On Friday, ten companies faced significant losses as investors reacted to poor earnings results and bleak forecasts for 2025.
On Thursday, Neurocrine Biosciences Inc. (NBIX) announced that its adjusted earnings per share (EPS) for the fourth quarter was $1.69, which is an increase from $1.54 the previous year and above the expected $1.56.
Neurocrine Biosciences, a specialist in neurological treatments, shared its fourth-quarter earnings on Thursday, February 6. While the company fell short of revenue expectations, its adjusted earnings per share (EPS) exceeded estimates by a considerable margin.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will hold its Q4 2024 Earnings Conference Call on February 6, 2025, at 4:30 PM ET. Key company participants include Todd Tushla, Kyle Gano, Matt Abernethy, Eric Benevich, and Eiry Roberts. The call will also feature various conference call participants from different financial institutions.
Neurocrine Biosciences (NBIX) reported quarterly earnings of $1 per share, which is lower than the Zacks Consensus Estimate of $1.56 per share. This is also a decrease compared to earnings of $1.44 per share from the same period last year.
Assess the anticipated performance of Neurocrine (NBIX) for the quarter ending December 2024 by going beyond the usual Wall Street revenue and profit predictions. Instead, focus on some important metrics to gain a clearer understanding of the company's outlook.
Neurocrine Biosciences shares are a good investment because of strong sales growth, especially after the FDA approved CRENESSITY in December 2024. While INGREZZA leads in sales, CRENESSITY, a new treatment for CAH, has the potential for significant growth, with first-year sales expected to reach $150 million. Investors should be prepared for fluctuations in the stock price around the Q4 earnings report and 2025 forecasts, particularly concerning the initial sales of CRENESSITY, which will be released after hours on Thursday.
SAN DIEGO, Jan. 28, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) has started a Phase 3 study to assess how effective, safe, and tolerable osavampator (previously known as NBI-1065845) is as an additional treatment alongside antidepressants for major depressive disorder (MDD). In April 2024, they shared positive initial results from the Phase 2 SAVITRI™ study involving adults with MDD.
SAN DIEGO, Jan. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) has announced the release of a special supplement in The Journal of Clinical Endocrinology & Metabolism (JCEM) that focuses on classic congenital adrenal hyperplasia (CAH). The supplement, named "Challenges and Opportunities in the Management of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency Throughout the Lifetime," includes eight review articles that explore the various clinical, psychosocial, treatment-related, and everyday challenges faced by those living with classic CAH.